...A. In the U.S., of course, we have a very large, scaled, strong free cash flow Pharmaceutical Distribution business, and we complement that with higher-margin, higher-growth businesses like our -- for instance, our specialty physician services business, which has a lot of higher-margin wraparound services with our biopharma manufacturer service businesses and our Animal Health business. B. In that segment, Cencora has a very strong Pharmaceutical Distribution business that we lead with. C. This year, we'll have over $2 billion of free cash flow. D. We're also doing strategic M&A. We recently made an investment in OneOncology, which is a natural evolution of our specialty business. E. We did the PharmaLex acquisition that I talked about. F. We're continuing to do opportunistic share repurchases. G. This year, we repurchased over $1 billion of our stock, which we're very pleased with, and then we're continuing to grow our dividend each year....
